Now a tradition, we have surveyed our global MDoutlook network of over 62,000 cancer treaters immediately following ASCO. By pulsing the largest database of cancer providers in the world, Arcas is the only organization that can present you the clinical impact of new data on cancer therapies and clinical drivers with robustness and detail.
Concentrating on key new data presented in Melanoma, Lung Cancer, Renal Cell Carcinoma, Prostate Cancer, Colorectal Cancer and Hepatocellular Carcinoma, we are distributing the results in separate reports. Based on a total response of more than 400 cancer treaters from a total of 27 countries, we are proud to present our analysis on all five disease areas:
* MDoutlook ASCO 2012 QP – Prostate
* MDoutlook ASCO 2012 QP – GI Cancers
* MDoutlook ASCO 2012 QP – NSCLC+RCC
* MDoutlook ASCO 2012 QP – Melanoma
MDoutlook activities are predicated on 3 critical principles: 1) Relevant and accurate insight directly from pre-validated treaters; 2) Robust coverage and 3) Rapid response. Insight is presented in reports that can be shared directly with senior management, and intelligence is enhanced by the review and feedback from key ThoughtLeaders in each disease covered.
You can also visit Oncology Business Review (OBR); their Editor’s Blog has a copy of the Prostate Cancer results published today.
If you have any questions or would like to discuss how MDoutlook can support your oncology intelligence needs for your strategic and tactical plans, please contact me directly.
President, The Arcas Group